<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430388</url>
  </required_header>
  <id_info>
    <org_study_id>VFAReumatoHC</org_study_id>
    <nct_id>NCT03430388</nct_id>
  </id_info>
  <brief_title>Yellow Fever Vaccine in Patients With Rheumatic Diseases</brief_title>
  <official_title>Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to World Health Organization (WHO), since December 2016, Brazil is showing a
      significant increase in cases of yellow fever in humans. In view of this, vaccination is
      suitable for residents and travelers to the risk area. However, for immunosuppressed patients
      there is a formal recommendation not to vaccinate with live virus vaccine. On the other hand,
      the safety and efficacy of the vaccine has been demonstrated in patients with HIV, and safety
      and seroconversion have also been demonstrated in patients with rheumatic disease who were
      inadvertently revaccinated for yellow fever. Faced with the impossibility of leaving the
      high-risk area for some patients the vaccination could be released to only those who have low
      level of immunosuppression as suggested by some recommendations of medical societies. The
      availability of a fractional vaccine in the State of São Paulo, which has proved its
      efficacy, opens the possibility of exposure to a lower number of copies of the virus in the
      first exposure of immunosuppressed patients, allowing, if necessary, a safer revaccination,
      after 28 days to obtain of a more effective immunogenic response. The objectives of the study
      are to evaluate the immune response of the immunization with fractional yellow fever vaccine
      (neutralizing antibodies) in patients with systemic autoimmune rheumatic diseases residing in
      a high-risk area. Secondarily, evaluate the possible association between immunogenicity and
      vaccination with: demographic data, clinical and laboratory activity of the disease in
      patients with chronic rheumatic diseases, evaluate the curve of viremia and report adverse
      events. Patients and healthy controls will be vaccinated for yellow fever in the Immunization
      Center of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
      (HC-FMUSP). The patients' screening for exclusion and inclusion criteria will be done at the
      rheumatology outpatient clinic after medical evaluation. For the controls will be the routine
      screening of the Immunization Center. The vaccination protocol will be a fractional dose of
      the yellow fever vaccine on day D0 for both groups. Patients will be evaluated on day D0, D5,
      D10, D30-4 and D365 and controls only on days D0, D10, D30-45 and D365 for aspartate
      aminotransferase (AST), alanine aminotransferase (ALT), platelets, urea and creatinine,
      immunoglobulin M (IgM) by immunofluorescence for Yellow Fever, viremia, autoantibodies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">February 24, 2019</completion_date>
  <primary_completion_date type="Actual">March 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with severe adverse events to the fractional dose of Yellow Fever vaccine</measure>
    <time_frame>10 days</time_frame>
    <description>Comparison of adverse events rates (based on the Brighton Collaboration diagnostic criteria) between rheumatic disease patients and healthy controls after Yellow Fever vaccine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with protective levels of antibodies against Yellow Fever vaccine</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of protective antibodies rates (measured by indirect immunofluorescence) against Yellow Fever virus between rheumatic disease patients and healthy controls after Yellow Fever vaccine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of number of patients with protective antibodies levels and disease activity in patients with chronic rheumatic diseases</measure>
    <time_frame>30 days</time_frame>
    <description>Association of number of patients with protective antibodies levels against yellow fever and disease activity in patients with chronic rheumatic diseases (measured by systemic lupus erythematosus disease activity index-SLEDAI for systemic lupus erythematosus patients, disease activity score-DAS28 for rheumatoid arthritis patients, manual muscle testing-MMT and disease activity score-DAS for inflammatory myopathies patients, Birmingham Vasculitis Activity Score-BVAS for primary vasculitis patients, juvenile arthritis disease activity score-JADAS for juvenile idiopathic arthritis patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with persistent protective levels of antibodies against Yellow Fever</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of protective antibodies rates (measured by indirect immunofluorescence) against Yellow Fever virus between rheumatic disease patients and healthy controls after Yellow Fever vaccine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Systemic Lupus</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Spondyloarthritis</condition>
  <condition>Inflammatory Myopathy</condition>
  <condition>Systemic Sclerosis</condition>
  <condition>Mixed Connective Tissue Disease</condition>
  <condition>Takayasu Arteritis</condition>
  <condition>Granulomatosis With Polyangiitis</condition>
  <condition>Sjogren's Syndrome</condition>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <condition>Juvenile Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>Rheumatic diseases patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Yellow Fever vaccine (17D)</intervention_name>
    <description>Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine</description>
    <arm_group_label>Rheumatic diseases patients</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatic disease under low immunosuppression (hydroxychloroquine, sulfasalazine or
             methotrexate plus prednisone up to 7,5mg/day or leflunomide plus prednisone up to
             7,5mg/day),

          -  Resident in high risk área for Yellow Fever

        Exclusion Criteria:

          -  Active disease

          -  Primary immunodeficiency

          -  History of anaphylactic response to vaccine components or egg allergy

          -  Living outside the risk area

          -  Do not meet criteria for low immunosuppression

          -  History of previous immunization with the yellow fever vaccine

          -  History of live virus vaccine up to 4 weeks before

          -  Individuals who do not agree to participate in the study and/or whose parents do not
             agree to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eloisa Bonfa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, SP - Brazil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eloisa Bonfa, MD, PhD</last_name>
    <phone>55 11 30617490</phone>
    <email>eloisa.bonfa@hc.fm.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nádia Aikawa, MD, PhD</last_name>
    <phone>55 11 30617490</phone>
    <email>nadia.aikawa@hc.fm.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eloisa Bonfa, MD, PhD</last_name>
      <phone>55 11 30617490</phone>
      <email>eloisa.bonfa@hc.fm.usp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990 Aug;33(8):1129-34.</citation>
    <PMID>1975175</PMID>
  </reference>
  <reference>
    <citation>Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315-24.</citation>
    <PMID>3358796</PMID>
  </reference>
  <reference>
    <citation>Barte H, Horvath TH, Rutherford GW. Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev. 2014 Jan 23;(1):CD010929. doi: 10.1002/14651858.CD010929.pub2. Review.</citation>
    <PMID>24453061</PMID>
  </reference>
  <reference>
    <citation>Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 2003 Feb 15;49(1):7-15.</citation>
    <PMID>12579588</PMID>
  </reference>
  <reference>
    <citation>Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 Feb 13;292(7):344-7. Review.</citation>
    <PMID>1090839</PMID>
  </reference>
  <reference>
    <citation>Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630-40.</citation>
    <PMID>1599520</PMID>
  </reference>
  <reference>
    <citation>Campi-Azevedo AC, de Almeida Estevam P, Coelho-Dos-Reis JG, Peruhype-Magalhães V, Villela-Rezende G, Quaresma PF, Maia Mde L, Farias RH, Camacho LA, Freire Mda S, Galler R, Yamamura AM, Almeida LF, Lima SM, Nogueira RM, Silva Sá GR, Hokama DA, de Carvalho R, Freire RA, Filho EP, Leal Mda L, Homma A, Teixeira-Carvalho A, Martins RM, Martins-Filho OA. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis. 2014 Jul 15;14:391. doi: 10.1186/1471-2334-14-391.</citation>
    <PMID>25022840</PMID>
  </reference>
  <reference>
    <citation>Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis. 2008 Mar 1;197 Suppl 2:S237-41. doi: 10.1086/522129. Review.</citation>
    <PMID>18419403</PMID>
  </reference>
  <reference>
    <citation>Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A; Paediatric Rheumatology International Trials Organisation. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009 May 15;61(5):658-66. doi: 10.1002/art.24516.</citation>
    <PMID>19405003</PMID>
  </reference>
  <reference>
    <citation>Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991 Oct;34(10):1218-27.</citation>
    <PMID>1930310</PMID>
  </reference>
  <reference>
    <citation>Esparza RH, Swaak T, Aarden L, Smeenk R. Complement-fixing antibodies to dsDNA detected by the immunofluorescence technique on Crithidia luciliae. A critical appraisal. J Rheumatol. 1985 Dec;12(6):1109-17.</citation>
    <PMID>3912506</PMID>
  </reference>
  <reference>
    <citation>Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12):2286-91.</citation>
    <PMID>7699630</PMID>
  </reference>
  <reference>
    <citation>Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91.</citation>
    <PMID>11838846</PMID>
  </reference>
  <reference>
    <citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725.</citation>
    <PMID>9324032</PMID>
  </reference>
  <reference>
    <citation>Kuter BJ, Ngai A, Patterson CM, Staehle BO, Cho I, Matthews H, Provost PJ, White CJ. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine. 1995 Aug;13(11):967-72.</citation>
    <PMID>8525689</PMID>
  </reference>
  <reference>
    <citation>Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med. 1989 Apr 6;320(14):892-7.</citation>
    <PMID>2538749</PMID>
  </reference>
  <reference>
    <citation>Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990 Aug;33(8):1101-7.</citation>
    <PMID>2202308</PMID>
  </reference>
  <reference>
    <citation>Lightfoot RW Jr, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ, Arend WP, Calabrese LH, Leavitt RY, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990 Aug;33(8):1088-93.</citation>
    <PMID>1975174</PMID>
  </reference>
  <reference>
    <citation>Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, Hicks JE, Levinson JE, Mier R, Pachman LM, Passo MH, Perez MD, Reed AM, Schikler KN, Smith M, Zemel LS, Rider LG. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum. 1999 Oct;42(10):2213-9.</citation>
    <PMID>10524696</PMID>
  </reference>
  <reference>
    <citation>Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D; Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Jan;68(1):18-24. doi: 10.1136/ard.2008.094870. Epub 2008 Jul 14.</citation>
    <PMID>18625618</PMID>
  </reference>
  <reference>
    <citation>Martins RM, Maia Mde L, Farias RH, Camacho LA, Freire MS, Galler R, Yamamura AM, Almeida LF, Lima SM, Nogueira RM, Sá GR, Hokama DA, de Carvalho R, Freire RA, Pereira Filho E, Leal Mda L, Homma A. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother. 2013 Apr;9(4):879-88. doi: 10.4161/hv.22982. Epub 2013 Jan 30.</citation>
    <PMID>23364472</PMID>
  </reference>
  <reference>
    <citation>Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990 Aug;33(8):1094-100.</citation>
    <PMID>2202307</PMID>
  </reference>
  <reference>
    <citation>Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55-78. Review.</citation>
    <PMID>4581554</PMID>
  </reference>
  <reference>
    <citation>Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009 Dec;68(12):1827-32. doi: 10.1136/ard.2008.101279. Epub 2008 Dec 3.</citation>
    <PMID>19054820</PMID>
  </reference>
  <reference>
    <citation>Oliveira AC, Mota LM, Santos-Neto LL, Simões M, Martins-Filho OA, Tauil PL. Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever. Arthritis Rheumatol. 2015 Feb;67(2):582-3. doi: 10.1002/art.38960.</citation>
    <PMID>25418753</PMID>
  </reference>
  <reference>
    <citation>Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010 May;69(5):798-806. doi: 10.1136/ard.2009.116657.</citation>
    <PMID>20413568</PMID>
  </reference>
  <reference>
    <citation>Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004 Feb;31(2):390-2.</citation>
    <PMID>14760812</PMID>
  </reference>
  <reference>
    <citation>Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 Jan;38(1):44-8.</citation>
    <PMID>7818570</PMID>
  </reference>
  <reference>
    <citation>Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010 Apr;62(4):465-72. doi: 10.1002/acr.20035.</citation>
    <PMID>20391500</PMID>
  </reference>
  <reference>
    <citation>Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C; EULAR Sjögren's Task Force. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010 Jun;69(6):1103-9. doi: 10.1136/ard.2009.110619. Epub 2009 Jun 28. Erratum in: Ann Rheum Dis. 2011 May;70(5):880.</citation>
    <PMID>19561361</PMID>
  </reference>
  <reference>
    <citation>Sidibe M, Yactayo S, Kalle A, Sall AA, Sow S, Ndoutabe M, Perea W, Avokey F, Lewis RF, Veit O. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali. Trans R Soc Trop Med Hyg. 2012 Jul;106(7):437-44. doi: 10.1016/j.trstmh.2012.04.002. Epub 2012 May 22.</citation>
    <PMID>22627101</PMID>
  </reference>
  <reference>
    <citation>Tanrıöver MD, Akar S, Türkçapar N, Karadağ Ö, Ertenli İ, Kiraz S. Vaccination recommendations for adult patients with rheumatic diseases. Eur J Rheumatol. 2016 Mar;3(1):29-35. Epub 2015 Oct 28. Review.</citation>
    <PMID>27708966</PMID>
  </reference>
  <reference>
    <citation>van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov;65(11):2737-47. doi: 10.1002/art.38098. Epub 2013 Oct 3.</citation>
    <PMID>24122180</PMID>
  </reference>
  <reference>
    <citation>van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011 Mar;70(3):414-22. doi: 10.1136/ard.2010.137216. Epub 2010 Dec 3.</citation>
    <PMID>21131643</PMID>
  </reference>
  <reference>
    <citation>van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2011 Apr;10(6):341-52. doi: 10.1016/j.autrev.2010.12.003. Epub 2010 Dec 20. Review.</citation>
    <PMID>21182987</PMID>
  </reference>
  <reference>
    <citation>Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002 Jun;61(6):554-8. Review.</citation>
    <PMID>12006334</PMID>
  </reference>
  <reference>
    <citation>Wu JT, Peak CM, Leung GM, Lipsitch M. Fractional dosing of yellow fever vaccine to extend supply: a modelling study. Lancet. 2016 Dec 10;388(10062):2904-2911. doi: 10.1016/S0140-6736(16)31838-4. Epub 2016 Nov 10.</citation>
    <PMID>27837923</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>Yellow Fever</keyword>
  <keyword>Rheumatic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Dermatomyositis</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
    <mesh_term>Yellow Fever</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Takayasu Arteritis</mesh_term>
    <mesh_term>Aortic Arch Syndromes</mesh_term>
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Mixed Connective Tissue Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

